The SG&A expenses related to the Tysabri ROW sales are reflected in the Tysabri ROW revenue as previously described on page 10.
Research and development
|Three Months Ended||Nine Months Ended|
|September 30||September 30|
|1.7||1.5||Depreciation and amortization||5.1||4.7|
R&D expenses decreased by $7.4 million to $37.0 million for the third quarter of 2012, from $44.4 million for the third quarter of 2011 primarily as a result of lower spend on early stage research activities that are not part of the Neotope separation and reduced spend on Tysabri development activities.